

Supplementary table 1. Demographics and baseline disease characteristics of the patients' groups

	Crohn's Disease	Ulcerative Colitis	Controls
No. of cases	12	7	19
Age (years; median and ranges)	14 (12–17)	10 (8–13)	12.7 (9-16)
M/F	7/5	3/4	11/8
Weight (Kg) (mean ± SD)	30.6 (± 12.2)	33.9 ± 13.1	36.2 ± 9.6
Height (cm) (mean ± SD)	133.8 (±19.1)	138.3 ± 22.1	140 ±25.3
BMI (Kg/cm ²) (mean ± SD)	16.4 ± 2.0	17.0 ± 2.2	20 ± 2.1
Disease duration (weeks; median and range)	6 (2-12)	8 (3- 12)	-
Disease Location			
Upper involvement	5/12 (42%)	0/6 (0%)	-
Lower involvement			
Ileum	0 (0%)	0 (0%)	-
Ileo-colon	12/12 (100%)	7/7 (100%)*	-
Colon			
total	-	7/7 (100%)	-
left sided	-	-	-
proctitis	-	-	-
Previous endoscopic assessment	0/12 (0%)	3/7 (57%)**	0/19 (0%)
Previous treatment			
Sulfasalazine	0/12 (0%)	0/7 (0%)	-
5-aminosalicylic acid drug	0/12 (0%)	0/7 (0%)	-
Steroid	0/12 (0%)	1/7 (8%)§	-
Current treatment			
Sulfasalazine	2/12 (25%)	0/7 (0%)	-
5-aminosalicylic acid drug	0/12 (0%)	3/7 (43%)	-
PCDAI (mean ± SD)	42.5 ± 11	-	
PUCAI (mean ± SD)	-	71.4 ± 7.5	-
CDEIS (mean ± SD)	13.5 ± 3.5	-	-
Baron's endoscopic score	-	2.7 ± 0.5	-

* ileum involvement as backwash ileitis; **Sigmoidoscopy in all of them; § steroid as enema
PCDAI, Pediatric Crohn's Disease Activity Index²²; PUCAI: Pediatric Ulcerative Colitis Activity Index²³;
CDEIS: Crohn's Disease Endoscopic Index of Severity²⁴; Baron's endoscopic score²⁵